We have identified three distinct HLA types of NPMc+ AML patients which differ in the disease incidence and evolution (Table 2): (i) in patients expressing HLA-B ́40, the presumed positive impact of the immune response occurrs mainly in the early phase of the disease and may prevent leukemia development. The gene discussed is HLA-B; the disease is acute myeloid leukemia.